<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>RedChip Upcoming Webinars</title>
    <link>https://www.redchip.com/webinar</link>
    <atom:link href="https://www.redchip.com/webinar/rss" rel="self" type="application/xml" />
    <description>Latest upcoming webinars from RedChip.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 08 Dec 2026 21:15:00 +0000</lastBuildDate>
    <ttl>15</ttl>
    <item>
      <title><![CDATA[Anixa Biosciences (NASDAQ: ANIX)]]></title>
      <link>https://www.redchip.com/webinar/ANIX/83349309450</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/ANIX/83349309450</guid>
      <pubDate>Tue, 20 Oct 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.]]></description>
    </item>
    <item>
      <title><![CDATA[Powering the Future: The Next Generation of Energy Infrastructure]]></title>
      <link>https://www.redchip.com/webinar/redchip/81805443130</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/redchip/81805443130</guid>
      <pubDate>Thu, 22 Oct 2026 13:30:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[Nexalin Technology]]></title>
      <link>https://www.redchip.com/webinar/NXL/88046611977</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/NXL/88046611977</guid>
      <pubDate>Mon, 26 Oct 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman.]]></description>
    </item>
    <item>
      <title><![CDATA[Venu Holding Corporation (NYSE American: VENU)]]></title>
      <link>https://www.redchip.com/webinar/VENU/87964071692</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/VENU/87964071692</guid>
      <pubDate>Wed, 28 Oct 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[Venu® Holding Corporation ("VENU") (NYSE American: VENU), founded by Colorado Springs entrepreneur J.W. Roth, is a premier owner, developer, and operator of luxury, experience-driven entertainment destinations. VENU's portfolio includes the award-winning Ford Amphitheater, Sunset Amphitheaters, Regent Bank Amphitheater, Phil Long Music Hall, The Hall at Bourbon Brothers, Bourbon Brothers Smokehouse and Tavern, Aikman Owners Clubs, and Roth's Sea & Steak, with venues operating and in development across Colorado, Georgia, Oklahoma, Tennessee, and Texas. The Company currently has six current projects representing approximately $1.5 billion in development, and was recently recognized by Forbes for its Luxe FireSuites® ownership model. VENU trades on NYSE American under the ticker VENU.]]></description>
    </item>
    <item>
      <title><![CDATA[60 Degrees Pharmaceuticals]]></title>
      <link>https://www.redchip.com/webinar/SXTP/83874994795</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/SXTP/83874994795</guid>
      <pubDate>Thu, 29 Oct 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[ASP Isotopes]]></title>
      <link>https://www.redchip.com/webinar/ASPI/89403250350</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/ASPI/89403250350</guid>
      <pubDate>Tue, 03 Nov 2026 21:15:00 +0000</pubDate>
      <description><![CDATA[This exclusive event will provide investors with an opportunity to gain critical insights into ASP Isotopes' strategic initiatives and technological advancements. The webinar will reaffirm the Company's confidence in its proprietary technology, robust leadership, and promising growth trajectory. ASP Isotopes will also highlight progress at its state-of-the-art isotope enrichment facilities in South Africa, where the commissioning of three key plants is underway. These include a Carbon-14 enrichment facility for healthcare and agrochemical applications, a Silicon-28 plant poised to revolutionize AI and quantum computing, and a Ytterbium-176 facility supporting cutting-edge radio-oncology therapies.]]></description>
    </item>
    <item>
      <title><![CDATA[Noble Africa]]></title>
      <link>https://www.redchip.com/webinar/NDRA/83554432651</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/NDRA/83554432651</guid>
      <pubDate>Wed, 04 Nov 2026 21:15:00 +0000</pubDate>
      <description><![CDATA[Noble Africa is developing one of the world's most unique integrated helium and liquefied natural gas (LNG) projects through its flagship Virginia Gas Project in South Africa. The Company's asset hosts one of the highest known commercially scalable helium concentrations globally - approximately 3%, well above typical global projects - while simultaneously producing LNG to supply South Africa's structurally undersupplied domestic energy market.

Phase 1 production is ramping toward nameplate capacity, positioning Noble Africa to become one of the few new commercial helium suppliers entering a market constrained by limited global supply and growing demand from semiconductor manufacturing, healthcare, aerospace, and other critical industries. Backed by substantial financing support from the U.S. Development Finance Corporation and additional committed funding for Phase 2, Noble Africa offers investors exposure to a rare, strategic asset with long-life reserves, multiple revenue streams, and significant production growth potential.]]></description>
    </item>
    <item>
      <title><![CDATA[Hawkeye Digital (OTC: HWKE)]]></title>
      <link>https://www.redchip.com/webinar/HWKE/83415488465</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/HWKE/83415488465</guid>
      <pubDate>Thu, 05 Nov 2026 21:15:00 +0000</pubDate>
      <description><![CDATA[Hawkeye Digital is creating a differentiated merchant banking and private equity platform designed to capitalize on the institutionalization of digital assets. Leveraging deep capital markets expertise and an established global network across blockchain and crypto, the Company identifies, acquires, and incubates high-potential businesses while providing investors with diversified exposure to one of the fastest-growing segments of global finance.]]></description>
    </item>
    <item>
      <title><![CDATA[BioVie]]></title>
      <link>https://www.redchip.com/webinar/BIVI/89396853693</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/BIVI/89396853693</guid>
      <pubDate>Tue, 08 Dec 2026 21:15:00 +0000</pubDate>
      <description><![CDATA[BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson’s disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company’s lead drug candidate bezisterim inhibits the production of tumor necrosis factor alpha (TNF-α) to reduce neuroinflammation and insulin resistance – both of which are drivers of Alzheimer’s and Parkinson’s. Bezisterim is also being evaluated to treat the neurological symptoms associated with long COVID, which are associated with persistent systematic inflammation and neuroinflammation. In liver disease, the Company is actively exploring partnerships for a Phase 3 trial to evaluate BIV201 (continuous infusion terlipressin) to reduce further decompensation in participants with liver cirrhosis and ascites. BIV201 has the potential to become the first therapeutic for ascites, a condition with 50% mortality rate within 12 months.]]></description>
    </item>
  </channel>
</rss>
